Correlation Between Serum Apoptotic Markers and Hepatitis C viral load In Chronic Hepatitis C Virus-Related Liver Disease | ||||
| Sohag Medical Journal | ||||
| Article 7, Volume 21, Issue 1, January 2017, Page 65-76 PDF (138.47 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/smj.2017.40006 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Eman Sabet | ||||
| Department of Internal medicine ; Faculty of medicine; Sohag University. | ||||
| Abstract | ||||
| Hepatitis C virus (HCV) is considered the most common etiology of chronic liver disease in Egypt. Developing non invasive tests that can predict liver injury represents a growing medical need. Considering that hepatocyte apoptosis plays a role in chronic hepatitis C pathogenesis; evaluation of the presence of different apoptotic markers that correlate with liver injury in HCV- related liver diseases could be a way for this achievement. The aim of the present study was to identify the correlation between serum apoptotic markers Bcl-2 and Bax with hepatitis C viral load in the chronic hepatitis C virus related liver diseases. The study included three groups ; group 1: 35 compensated chronic HCV patients without any suspected evidence of liver cirrhosis and with Child - Pugh score of 5-6 (class A), Group 2: 35 decompensated chronic HCV patients with Child - Pugh score of 10-15 (class C) and group 3: 15 healthy volunteers as a control group. The results collectively suggest that statistically significant correlations were noticed between serum Bcl-2, Bax, Bcl-2/Bax ratio and HCV PCR in chronic hepatitis C virus-related liver disease. | ||||
| Keywords | ||||
| Chronic HCV; Hepatitis; Bcl-2; Bax | ||||
|
Supplementary Files
|
||||
| References | ||||
|
1- WHO (2016). Global Hepatitis Programme, new recommendations in the updated WHO guidelines for life screening, care and treatment of persons with chronic hepatitis C infection.
2- Esmat, G. (2013). Hepatitis C in the Eastern Mediterranean region. Eastern Mediterranean health journal; 19 (7).
3- Kar P and Hazam RK. (2009). Hepatitis C, goals of therapy and monitoring of therapy. International Journal of Hepatology; 48:36 – 44.
4- Guilherme A, Carine PA, Sheila S et al. (2012). Altered of apoptotic markers of both extrinsic and intrinsic pathways induced by hepatitis C virus infection in peripheral blood mononuclear cells. Virol J; 2012; 9:314.
5- Garcia S (2012). The secrets of the Bcl-2 family. Cell Death Differ 19(11): P. 1733 – 40.
6- Panasiuk A, Parfieniuk A, Zak J and Filisiak R (2010). Association among Fas expreeion in leucocytes, serum Fas and Fas – ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int; 30; 472 – 478.
7- Chen N, Deng T and Chen P (2000). The regulation of apoptosis byBcl-2, Bcl-X(L), Bcl-alpha and Bax in chronic liver disease. Zhonghua Nei Ke Za Zhi; 39: 808-810.
8- Papakyriakou P, Tzardi M, Valatas V et al. (2002). Apoptosis and apoptosis related proteins in chronic viral liver disease. Apoptosis; 7: 133-141.
9- Alenzi Q, EL-Nashar M, AL-Ghamdi S et al. (2010). Investigation of Bcl-2 and PCNA in Hepatocellular Carcinoma: Relation to Chronic HCV. Journal of the Egyptian Nat. Cancer Inst.; Vol. 22, No. 1.
10- Nakamoto Y, Kaneko S and Kobayashi K (2002). Increased susceptibility to apoptosis and attenuated Bcl-2 expression in T lymphocytes and monocytes from patients with advanced chronic hepatitis C. J Leukoc Biol; 72: 49-55.
11- El-Bendary M, Hawas S, Elhammady D et al. (2014). Expression of Fas (CD95) and Bcl-2 in peripheral blood mononuclear cells in patients with chronic HCV
and schistosomiasis.
| ||||
|
Statistics Article View: 139 PDF Download: 107 |
||||
